PMID- 32372523
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210802
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 177
IP  - 15
DP  - 2020 Aug
TI  - Cyclic AMP in dendritic cells: A novel potential target for disease-modifying 
      agents in asthma and other allergic disorders.
PG  - 3363-3377
LID - 10.1111/bph.15095 [doi]
AB  - Allergic diseases are immune disorders that are a global health problem, 
      affecting a large portion of the world's population. Allergic asthma is a 
      heterogeneous disease that alters the biology of the airway. A substantial 
      portion of patients with asthma do not respond to conventional therapies; thus, 
      new and effective therapeutics are needed. Dendritic cells (DCs), antigen 
      presenting cells that regulate helper T cell differentiation, are key drivers of 
      allergic inflammation but are not the target of current therapies. Here we review 
      the role of dendritic cells in allergic conditions and propose a 
      disease-modifying strategy for treating allergic asthma: cAMP-mediated inhibition 
      of dendritic cells to blunt allergic inflammation. This approach contrasts with 
      current treatments that focus on treating clinical manifestations of airway 
      inflammation. Disease-modifying agents that target cAMP and its signalling 
      pathway in dendritic cells may provide a novel means to treat asthma and other 
      allergic diseases.
CI  - (c) 2020 The British Pharmacological Society.
FAU - Chinn, Amy M
AU  - Chinn AM
AD  - Department of Pharmacology, University of California, San Diego, La Jolla, 
      California, USA.
FAU - Insel, Paul A
AU  - Insel PA
AD  - Department of Pharmacology, University of California, San Diego, La Jolla, 
      California, USA.
AD  - Department of Medicine, University of California, San Diego, La Jolla, 
      California, USA.
LA  - eng
GR  - R56 AI110505/AI/NIAID NIH HHS/United States
GR  - T32 GM007752/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200621
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - E0399OZS9N (Cyclic AMP)
SB  - IM
MH  - *Asthma/drug therapy
MH  - Cyclic AMP
MH  - Dendritic Cells
MH  - Humans
MH  - *Hypersensitivity/drug therapy
MH  - Th2 Cells
PMC - PMC7348084
COIS- The authors have no conflicts of interest.
EDAT- 2020/05/07 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/08/01
CRDT- 2020/05/07 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/03/27 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2021/08/01 00:00 [pmc-release]
AID - BPH15095 [pii]
AID - 10.1111/bph.15095 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2020 Aug;177(15):3363-3377. doi: 10.1111/bph.15095. Epub 2020 Jun 
      21.